Nicox Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Nicox has been growing earnings at an average annual rate of 64.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 51.3% per year.
Belangrijke informatie
64.6%
Groei van de winst
69.8%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 30.8% |
| Inkomstengroei | -51.3% |
| Rendement op eigen vermogen | -38.1% |
| Nettomarge | -485.7% |
| Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Nicox geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 23 | 4 | -17 | 7 | 0 |
| 31 Mar 23 | 3 | -23 | 7 | 0 |
| 31 Dec 22 | 3 | -28 | 7 | 0 |
| 30 Sep 22 | 5 | -38 | 7 | 0 |
| 30 Jun 22 | 7 | -49 | 7 | 0 |
| 31 Mar 22 | 7 | -46 | 7 | 0 |
| 31 Dec 21 | 7 | -44 | 7 | 0 |
| 30 Sep 21 | 10 | -29 | 7 | 0 |
| 30 Jun 21 | 12 | -15 | 6 | 0 |
| 31 Mar 21 | 12 | -17 | 7 | 0 |
| 31 Dec 20 | 13 | -18 | 7 | 0 |
| 30 Sep 20 | 8 | -25 | 7 | 0 |
| 30 Jun 20 | 4 | -33 | 7 | 0 |
| 31 Mar 20 | 5 | -26 | 8 | 0 |
| 31 Dec 19 | 7 | -19 | 8 | 0 |
| 30 Sep 19 | 8 | -15 | 8 | 0 |
| 30 Jun 19 | 9 | -11 | 9 | 0 |
| 31 Mar 19 | 7 | -15 | 9 | 0 |
| 31 Dec 18 | 4 | -18 | 10 | 0 |
| 30 Jun 18 | 3 | -4 | 9 | 0 |
| 31 Mar 18 | 2 | -6 | 9 | 0 |
| 31 Dec 17 | 2 | -8 | 10 | 0 |
| 30 Jun 17 | 0 | -6 | 9 | -7 |
| 31 Mar 17 | 0 | -6 | 9 | -3 |
| 31 Dec 16 | 0 | -7 | 9 | 0 |
| 30 Sep 16 | 0 | -15 | 9 | 5 |
| 30 Jun 16 | 0 | -22 | 9 | 10 |
| 31 Mar 16 | 0 | -21 | 10 | 8 |
| 31 Dec 15 | 0 | -20 | 11 | 6 |
| 30 Jun 15 | 4 | -21 | 20 | 5 |
| 31 Mar 15 | 5 | -22 | 22 | 5 |
| 31 Dec 14 | 6 | -22 | 24 | 4 |
| 30 Jun 14 | 2 | -13 | 14 | 3 |
| 31 Mar 14 | 1 | -13 | 13 | 4 |
| 31 Dec 13 | 0 | -11 | 11 | 4 |
Kwaliteitswinsten: ALCOX is currently unprofitable.
Groeiende winstmarge: ALCOX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if ALCOX's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare ALCOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ALCOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: ALCOX has a negative Return on Equity (-38.13%), as it is currently unprofitable.